Trial Profile
A Double- Blind, Randomized, Placebo and Active Controlled, Multi-Center Study to Investigate Efficacy and Safety After Oral Administration of 2 and 3 mg ZK 283197, 1 mg 17ß-Estradiol and Placebo Once Daily for 8 Weeks in Postmenopausal Women With Hot Flushes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs ZK 283197 (Primary) ; Estradiol
- Indications Hot flashes
- Focus Therapeutic Use
- Sponsors Bayer; Bayer HealthCare Pharmaceuticals
- 12 Jul 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 01 Sep 2012 Planned number of patients changed from 112 to 118.
- 05 Feb 2009 Actual patient numbers (112) added as reported by ClinicalTrials.gov.